Macleods 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


12345678»
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Factors Associated with Incomplete Adherence to Dolutegravir-Based Antiretroviral Therapy in Southwestern Uganda. (Pubmed Central) -  Aug 4, 2025   
    Incident headaches were associated with incomplete adherence to TLD in southwestern Uganda, while established pill-taking routines were associated with better adherence. Dolutegravir-associated weight gain did not impact adherence in this setting.
  • ||||||||||  efavirenz / Generic mfg., dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Blood pressure, weight change and incident hypertension after switching to dolutegravir in treatment-experienced people living with HIV. (Pubmed Central) -  Jul 24, 2025   
    P=N/A
    Following the initial increase in BW on TLE, a larger increase in BP and a higher risk of incident hypertension was associated with switching antiretroviral therapy from TLE to TLD. Focussing on BP control while on DTG and timely initiation of antihypertensive drug therapy can help to reduce the burden of hypertension in PLHIV with their inherent increased cardiovascular risk.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    SAME SCENARIO  (E-POSTER AREA) -  May 25, 2025 - Abstract #ESPID2025ESPID_1190;    
    Learning Points/Discussion - High adherence to ART saves the HIV patients' lives as well as significantly improves their quality of lives. - In patients with progressed HIV -infection: various infection agents can provoke neurological impairments.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    HIV-HCV COINFECTION IN PREGNANCY: CAN DIRECT-ACTING ANTIVIRAL AGENTS REDUCE THE RISK OF VERTICAL TRANSMISSION? (E-POSTER AREA) -  May 25, 2025 - Abstract #ESPID2025ESPID_1155;    
    While sofosbuvir-ledipasvir is not pan-genotypic, it has the most safety and efficacy evidence in this context. This high-risk case suggests that DAA treatment during pregnancy, even in later stages, may reduce vertical transmission of HCV.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Evaluation of cytokine levels in HIV-infected individuals on therapy with tenofovir, lamivudine, and dolutegravir. (Pubmed Central) -  May 14, 2025   
    These findings suggested that TDF/3TC/DTG treatment modulated cytokines, reducing chronic inflammation and improving the immune response in PLWHA. The decrease in anti-inflammatory cytokines, such as IL-4 and IL-10, may be associated with better regulation of the immune system, resulting in greater control of infection and a balanced inflammatory response.
  • ||||||||||  efavirenz / Generic mfg., zidovudine / Generic mfg., dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Journal:  Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART. (Pubmed Central) -  May 13, 2025   
    1000 copies/mL on first-line ART, mostly tenofovir-emtricitabine-efavirenz...Among adults switching to TLD with detectable HIV-1 RNA and substantial tenofovir and lamivudine resistance, a high proportion maintained virologic suppression up to 158 weeks. Emergent dolutegravir resistance occurred in ~1% of participants after 2-3 years on second-line TLD.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART. (Pubmed Central) -  May 13, 2025   
    The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Journal:  Kaposi sarcoma in an HIV-infected patient with high CD4 count: a case report and literature review. (Pubmed Central) -  May 12, 2025   
    This case report describes an 18-year-old male with vertical HIV infection, managed on a regimen of dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF), and with a recent CD4 count of 627cells/mm3and recent viral load of 378 copies/ml, presented with exacerbation of shortness of breath, productive cough with blood-tinged sputum, and a diffuse skin rash...The case underlines that though epidemic Kaposi sarcoma is often a disease of immunosuppressed people caused by retroviral infection, there is still the possibility in those with high CD4 counts despite viral load remains low. A high level of suspicion in high-risk patients presenting with characteristic skin lesions is critical for early diagnosis and prompt initiation of available treatment options for a better patient outcome.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Evaluation of people living with HIV presenting with dolutegravir resistance in Kenya () -  May 10, 2025 - Abstract #IASHIV2025IAS_HIV_938;    
    Routine safety laboratory monitoring is generally recommended in PWHs on switching therapy. 16 (73%) with INSTI resistance were treatment experienced PLHIV with multiple DRMs while 3 (14%) were on 1st line TDF/3TC/DTG and only had 1 DRM each after 17
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    HIV treatment outcomes following HIV acquisition on oral PrEP in Western Kenya () -  May 10, 2025 - Abstract #IASHIV2025IAS_HIV_928;    
    Efforts to support barriers to adherence for both PrEP and ART are needed to avert HIV acquisition and maintain viral suppression. As long-acting PrEP modalities with potential cross-resistance to ART are rolled out, further studies are needed to monitor the effect of PrEP-selected ARV resistance on virologic outcomes on ART.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Journal:  Antibiotic prescription patterns and associated symptoms in children living with HIV at Arthur Davison Children's Hospital in Ndola, Zambia. (Pubmed Central) -  Mar 5, 2025   
    Children who were on abacavir/lamivudine/dolutegravir regimen presented with more symptoms (48.8%) compared to those on tenofovir alafenamide/lamivudine/dolutegravir (21.0%) and tenofovir disoproxil fumarate/lamivudine/dolutegravir (18.2%) (p?=?0.006)...Co-trimoxazole was the most commonly (38.0%) prescribed, while erythromycin (2.0%) and Cephalexin (2.0%) were the least...Despite co-trimoxazole being the prophylactic drug among HIV-positive children, it was the most common antibiotic among children presenting with symptoms suggestive of an infection. This calls for the prudent use of co-trimoxazole to avoid its resistance.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Distinct Metabolic and Inflammation Signatures in Urban vs Rural Ugandan Youth With HIV (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1450;    
    Median viral load was 112 copies/mL, 52% rural vs 96% urban YPHIV had HIV-RNA <50 copies/mL, 93% of YPHIV were on TDF/3TC/DTG...The monocyte activation marker sCD14, was associated with HIV status and remained elevated in rural YPHIV even after adjusting for differences in HIV factors. Increasing the inclusion of rural populations in SSA is paramount as we focus on preventing cardiometabolic comorbidities in aging YPHIV.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Enhanced Adherence Counselling Among Adolescents With Detectable Viremia in Cameroon (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1436;    
    We herein evaluated the virological outcomes after enhanced adherence counselling (EAC) among ADLHIV with non-VS and low-level viremia (LLV) in the era of tenofovir-lamivudine-dolutegravir (TLD) in Cameroon...Conclusions In LMICs transitioning to TLD, an effective EAC would substantially improve ART outcomes among ADLHIV experiencing non-VS. In context, LMICs are encouraged to accompany the transition to pediatric dolutegravir-containing regimens with a robust adherence support strategy for ADLHIV with detectable VL to achieve elimination of pediatric AIDS by 2030.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Transitioning Adolescents With HIV to TDF/3TC+DTG Improves Virologic Outcome: CIPHER-ADOLA Study (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1433;    
    However, VR occurs in some cases, especially when switching from a DTG-based regimens. Thus, scaling-up the transition of ADLHIV to TLD, regardless of previous exposure to TDF/3TC/EFV and baseline VL, would contribute to markedly decreasing, down toward eliminating paediatric AIDS.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    HIV Drug Resistance by Next-Generation Sequencing After Transition to TLD in Uganda and South Africa (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1321;    
    Background Studies have identified an increased risk of dolutegravir (DTG) resistance in people with nucleos(t)ide (NRTI) resistance after transitioning from non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) to tenofovir/lamivudine/dolutegravir (TLD)...However, no study participants, including those with resistance to TDF and 3TC at the time of TLD transition or 24 weeks later, had resistance to DTG at the 2-20% thresholds after one year on TLD. Conclusions In a cohort of approximately 1,000 people who transitioned from NNRTI-containing ART to TLD in public sector clinics in Uganda and South Africa, resistance to TDF and FTC at transition was not associated with emergent DTG resistance, including minority variants.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Impact of Gestational Diabetes on Pregnancy Outcomes in South African Women Living With HIV (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1006;    
    Methods The ORCHID study enrolled pregnant women with HIV (WLH) receiving tenofovir+lamivudine+dolutegravir and a comparison group of HIV-seronegative (HIV-) women (eligibility: age >16y, <18w gestational age (GA) at enrollment, not known with diabetes or hypertension) in Cape Town, South Africa...Conclusions These novel findings suggest that maternal HIV infection may attenuate the known effects of GDM on LGA deliveries. Further research is required to understand what mechanisms may drive such an attenuation, and more generally to the long-term implications of GDM diagnoses for WLH and their infants.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Impact of TLD on Birth Outcomes in South African Women: The ORCHID Cohort (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_1005;    
    Background The global shift to tenofovir+lamivudine+dolutegravir (TLD) has improved viral suppression in women living with HIV (WLH) in pregnancy but there are limited data on birth outcomes with TLD use...For example, compared to women with normal BMI, women with class 1 obesity (BMI 30-35) experienced decreased odds of prematurity (AOR 0.59, 95% CI 0.36-0.96), LBW (AOR 0.49, 0.31-0.77), and SGA (AOR 0.52, 95% CI 0.33-0.80); Obesity classes 2&3 (BMI >35) decreased the odds of LBW (AOR 0.57, 95% CI 0.37-0.88), and SGA (AOR 0.38, 95% CI 0.23-0.61), and increased the odds of LGA (AOR 4.51, 95% CI 2.70-7.74). Conclusions These results suggest few meaningful differences in birth outcomes between WLH on TLD and HIV-negative women in this setting where both HIV and obesity are prevalent, while maternal BMI appears to be the major driver of birth outcomes in this cohort.
  • ||||||||||  Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Cimduo (lamivudine/tenofovir disoproxil fumarate) / Cipla, Celltrion, Macleods, Viatris, Sun Pharma, Aurobindo, Hetero
    Efficacy of Switching to Ainuovirine-Based Antiretroviral Regimen in Virologically Suppressed PWH (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_901;    
    Conclusions VS was well preserved in PWH with second- or third-line switch to ANV/3TC/TDF through 96 weeks. Immunologic outcomes might favor a "same-class" switch to ainuovirine-based regimen, and warranted further investigation into the changes in the viral reservoir and immune functionality of VS PWH switching antiretroviral regimen.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    LA-ART for Breastfeeding Women With HIV in Zimbabwe: Clinical Impact and Cost-Effectiveness (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_635;    
    We modeled 2 ART approaches immediately after delivery: standard of care (SOC: continuation of TLD) and LA-ART (switching from TLD to cabotegravir/rilpivirine [LA-CAB/RPV])...Conclusions LA-ART for breastfeeding women with adherence challenges to oral TLD could reduce infant infections. If efficacy is confirmed in postpartum women, LA-ART for women without viral suppression at delivery would improve outcomes and save money; for women with viral suppression, it would be cost-effective in Zimbabwe if costs were ?$7/month.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Neuropsychiatric Outcomes in Adults With HIV and TB on Twice-Daily BIC/FTC/TAF With Rifampicin (Poster Hall) -  Mar 3, 2025 - Abstract #CROI2025CROI_631;    
    P2
    6 and was reported in 73% of individuals in the BIC arm and 88% in the DTG arm. Conclusions The use of double-dose bictegravir was not significantly associated with a greater number of neuropsychiatric events than double-dose dolutegravir; and none of the identified events required neuropsychiatry interventions; treatment disruption or dose modifications in this study .
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare
    Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir (San Francisco Ballroom B) -  Mar 3, 2025 - Abstract #CROI2025CROI_234;    
    Conclusions This work provides the first clinical evidence of selection of NC mutations with TLD failure and of decreased DTG susceptibility from the combination of NC and IN mutations. Our findings support further investigation of the potential contributions of mutations outside of IN to VF of TLD.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods, Tivicay (dolutegravir) / ViiV Healthcare, lamivudine/zidovudine / Generic mfg.
    Retrospective data, Journal:  Resistance to Dolutegravir in Treatment-experienced Patients in South Africa: A Retrospective Cohort Study. (Pubmed Central) -  Mar 3, 2025   
    Over 60% of patients with prior treatment experience who had been on dolutegravir-based ART for over two years and experienced virologic failure had intermediate or high level dolutegravir resistance. This suggests that criteria for GART used are too stringent, which has resource implications in programmatic settings where access to resistance testing for individual management is limited.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial primary completion date:  Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis (clinicaltrials.gov) -  Feb 18, 2025   
    P2,  N=30, Active, not recruiting, 
    This suggests that criteria for GART used are too stringent, which has resource implications in programmatic settings where access to resistance testing for individual management is limited. Trial primary completion date: Feb 2025 --> May 2025